A citation-based method for searching scientific literature

A Sheth, S Escobar-Alvarez, J Gardner, L Ran, M L Heaney, D A Scheinberg. Cell Death Dis 2014
Times Cited: 31







List of co-cited articles
173 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mitochondria and cancer.
Douglas C Wallace. Nat Rev Cancer 2012
19

A mitochondrial ribosomal and RNA decay pathway blocks cell proliferation.
Uwe Richter, Taina Lahtinen, Paula Marttinen, Maarit Myöhänen, Dario Greco, Giuseppe Cannino, Howard T Jacobs, Niina Lietzén, Tuula A Nyman, Brendan J Battersby. Curr Biol 2013
74
19

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.
Andrew J Souers, Joel D Leverson, Erwin R Boghaert, Scott L Ackler, Nathaniel D Catron, Jun Chen, Brian D Dayton, Hong Ding, Sari H Enschede, Wayne J Fairbrother,[...]. Nat Med 2013
19

Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.
Mona D Lee, Yuhong She, Michael J Soskis, Christopher P Borella, Jeffrey R Gardner, Paula A Hayes, Benzon M Dy, Mark L Heaney, Mark R Philips, William G Bornmann,[...]. J Clin Invest 2004
76
16

Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia.
Marko Skrtić, Shrivani Sriskanthadevan, Bozhena Jhas, Marinella Gebbia, Xiaoming Wang, Zezhou Wang, Rose Hurren, Yulia Jitkova, Marcela Gronda, Neil Maclean,[...]. Cancer Cell 2011
396
16

SIRT4 protein suppresses tumor formation in genetic models of Myc-induced B cell lymphoma.
Seung Min Jeong, Annie Lee, Jaewon Lee, Marcia C Haigis. J Biol Chem 2014
76
16

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.
Nathalie A Johnson, Kerry J Savage, Olga Ludkovski, Susana Ben-Neriah, Ryan Woods, Christian Steidl, Martin J S Dyer, Reiner Siebert, John Kuruvilla, Richard Klasa,[...]. Blood 2009
410
16

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
Yasuhiro Oki, Mansoor Noorani, Pei Lin, Richard E Davis, Sattva S Neelapu, Long Ma, Mohamed Ahmed, Maria Alma Rodriguez, Fredrick B Hagemeister, Nathan Fowler,[...]. Br J Haematol 2014
228
16

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Roland Schmitz, Ryan M Young, Michele Ceribelli, Sameer Jhavar, Wenming Xiao, Meili Zhang, George Wright, Arthur L Shaffer, Daniel J Hodson, Eric Buras,[...]. Nature 2012
550
16

Overexpression of peptide deformylase in breast, colon, and lung cancers.
Harsharan Randhawa, Shireen Chikara, Drew Gehring, Tuba Yildirim, Jyotsana Menon, Katie M Reindl. BMC Cancer 2013
16
31

mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc.
Kenta Masui, Kazuhiro Tanaka, David Akhavan, Ivan Babic, Beatrice Gini, Tomoo Matsutani, Akio Iwanami, Feng Liu, Genaro R Villa, Yuchao Gu,[...]. Cell Metab 2013
257
12

MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27(KIP1.).
M T Gómez-Casares, E García-Alegria, C E López-Jorge, N Ferrándiz, R Blanco, S Alvarez, J P Vaqué, G Bretones, J M Caraballo, P Sánchez-Bailón,[...]. Oncogene 2013
45
12

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma.
Kieron Dunleavy, Stefania Pittaluga, Myron S Czuczman, Sandeep S Dave, George Wright, Nicole Grant, Margaret Shovlin, Elaine S Jaffe, John E Janik, Louis M Staudt,[...]. Blood 2009
390
12


Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers.
Wyndham H Wilson, Kieron Dunleavy, Stefania Pittaluga, Upendra Hegde, Nicole Grant, Seth M Steinberg, Mark Raffeld, Martin Gutierrez, Bruce A Chabner, Louis Staudt,[...]. J Clin Oncol 2008
224
12

A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.
Leandro C Cerchietti, Alexandru F Ghetu, Xiao Zhu, Gustavo F Da Silva, Shijun Zhong, Marilyn Matthews, Karen L Bunting, Jose M Polo, Christophe Farès, Cheryl H Arrowsmith,[...]. Cancer Cell 2010
211
12

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Tina Marie Green, Ken H Young, Carlo Visco, Zijun Y Xu-Monette, Attilio Orazi, Ronald S Go, Ole Nielsen, Ole V Gadeberg, Torben Mourits-Andersen, Mikael Frederiksen,[...]. J Clin Oncol 2012
466
12

Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors.
B Tolani, R Gopalakrishnan, V Punj, H Matta, P M Chaudhary. Oncogene 2014
73
12

B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
Shaoying Li, Pei Lin, Luis E Fayad, Patrick A Lennon, Roberto N Miranda, C Cameron Yin, E Lin, L Jeffrey Medeiros. Mod Pathol 2012
188
12

Double-hit B-cell lymphomas.
Sietse M Aukema, Reiner Siebert, Ed Schuuring, Gustaaf W van Imhoff, Hanneke C Kluin-Nelemans, Evert-Jan Boerma, Philip M Kluin. Blood 2011
459
12

Low-intensity therapy in adults with Burkitt's lymphoma.
Kieron Dunleavy, Stefania Pittaluga, Margaret Shovlin, Seth M Steinberg, Diane Cole, Cliona Grant, Brigitte Widemann, Louis M Staudt, Elaine S Jaffe, Richard F Little,[...]. N Engl J Med 2013
202
12

A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).
Graham M Mead, Sharon L Barrans, Wendi Qian, Jan Walewski, John A Radford, Max Wolf, Simon M Clawson, Sally P Stenning, Claire L Yule, Andrew S Jack. Blood 2008
140
12

MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Anamarija M Perry, Yuridia Alvarado-Bernal, Javier A Laurini, Lynette M Smith, Graham W Slack, King L Tan, Laurie H Sehn, Kai Fu, Patricia Aoun, Timothy C Greiner,[...]. Br J Haematol 2014
127
12

Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Sharon Barrans, Simon Crouch, Alex Smith, Kathryn Turner, Roger Owen, Russell Patmore, Eve Roman, Andrew Jack. J Clin Oncol 2010
406
12

BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma.
Joydeep Bhadury, Lisa M Nilsson, Somsundar Veppil Muralidharan, Lydia C Green, Zhoulei Li, Emily M Gesner, Henrik C Hansen, Ulrich B Keller, Kevin G McLure, Jonas A Nilsson. Proc Natl Acad Sci U S A 2014
151
12

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.
Ajay K Gopal, Brad S Kahl, Sven de Vos, Nina D Wagner-Johnston, Stephen J Schuster, Wojciech J Jurczak, Ian W Flinn, Christopher R Flowers, Peter Martin, Andreas Viardot,[...]. N Engl J Med 2014
734
12

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Nathalie A Johnson, Graham W Slack, Kerry J Savage, Joseph M Connors, Susana Ben-Neriah, Sanja Rogic, David W Scott, King L Tan, Christian Steidl, Laurie H Sehn,[...]. J Clin Oncol 2012
627
12

Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.
Sally E Trabucco, Rachel M Gerstein, Andrew M Evens, James E Bradner, Leonard D Shultz, Dale L Greiner, Hong Zhang. Clin Cancer Res 2015
96
12

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.
Adam M Petrich, Mitul Gandhi, Borko Jovanovic, Jorge J Castillo, Saurabh Rajguru, David T Yang, Khushboo A Shah, Jeremy D Whyman, Frederick Lansigan, Francisco J Hernandez-Ilizaliturri,[...]. Blood 2014
279
12

Inhibition of c-Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation.
Xiao-Na Pan, Jia-Jie Chen, Le-Xun Wang, Ruo-Zhi Xiao, Ling-Ling Liu, Zhi-Gang Fang, Quentin Liu, Zi-Jie Long, Dong-Jun Lin. PLoS One 2014
58
12

Hallmarks of cancer: the next generation.
Douglas Hanahan, Robert A Weinberg. Cell 2011
12

MYC on the path to cancer.
Chi V Dang. Cell 2012
12

Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease.
Rebecca Lamb, Bela Ozsvari, Camilla L Lisanti, Herbert B Tanowitz, Anthony Howell, Ubaldo E Martinez-Outschoorn, Federica Sotgia, Michael P Lisanti. Oncotarget 2015
283
12

Inhibition of human peptide deformylase disrupts mitochondrial function.
Sindy Escobar-Alvarez, Jeffrey Gardner, Aneesh Sheth, Giovanni Manfredi, Guangli Yang, Ouathek Ouerfelli, Mark L Heaney, David A Scheinberg. Mol Cell Biol 2010
26
15

On the origin of cancer cells.
O WARBURG. Science 1956
9

Mitochondrial import efficiency of ATFS-1 regulates mitochondrial UPR activation.
Amrita M Nargund, Mark W Pellegrino, Christopher J Fiorese, Brooke M Baker, Cole M Haynes. Science 2012
554
9

Mitochondrial form and function.
Jonathan R Friedman, Jodi Nunnari. Nature 2014
794
9

Mitonuclear protein imbalance as a conserved longevity mechanism.
Riekelt H Houtkooper, Laurent Mouchiroud, Dongryeol Ryu, Norman Moullan, Elena Katsyuba, Graham Knott, Robert W Williams, Johan Auwerx. Nature 2013
599
9

MYC oncogene in myeloid neoplasias.
M Dolores Delgado, Marta Albajar, M Teresa Gomez-Casares, Ana Batlle, Javier León. Clin Transl Oncol 2013
42
9

The proto-oncogene c-myc in hematopoietic development and leukemogenesis.
Barbara Hoffman, Arshad Amanullah, Marianna Shafarenko, Dan A Liebermann. Oncogene 2002
172
9


Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Georg Lenz, George W Wright, N C Tolga Emre, Holger Kohlhammer, Sandeep S Dave, R Eric Davis, Shannon Carty, Lloyd T Lam, A L Shaffer, Wenming Xiao,[...]. Proc Natl Acad Sci U S A 2008
677
9

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Zheng Zhou, Laurie H Sehn, Alfred W Rademaker, Leo I Gordon, Ann S Lacasce, Allison Crosby-Thompson, Ann Vanderplas, Andrew D Zelenetz, Gregory A Abel, Maria A Rodriguez,[...]. Blood 2014
480
9

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.
Wyndham H Wilson, Sin-Ho Jung, Pierluigi Porcu, David Hurd, Jeffrey Johnson, S Eric Martin, Myron Czuczman, Raymond Lai, Jonathan Said, Amy Chadburn,[...]. Haematologica 2012
133
9

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Heike Horn, Marita Ziepert, Claudia Becher, Thomas F E Barth, Heinz-Wolfram Bernd, Alfred C Feller, Wolfram Klapper, Michael Hummel, Harald Stein, Martin-Leo Hansmann,[...]. Blood 2013
368
9

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Kerry J Savage, Nathalie A Johnson, Susana Ben-Neriah, Joseph M Connors, Laurie H Sehn, Pedro Farinha, Douglas E Horsman, Randy D Gascoyne. Blood 2009
450
9

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma.
Matthias Pfeifer, Michael Grau, Dido Lenze, Sören-Sebastian Wenzel, Annette Wolf, Brigitte Wollert-Wulf, Kerstin Dietze, Hendrik Nogai, Benjamin Storek, Hannelore Madle,[...]. Proc Natl Acad Sci U S A 2013
188
9

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles.
David Cunningham, Eliza A Hawkes, Andrew Jack, Wendi Qian, Paul Smith, Paul Mouncey, Christopher Pocock, Kirit M Ardeshna, John A Radford, Andrew McMillan,[...]. Lancet 2013
325
9

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.
Wyndham H Wilson, Owen A O'Connor, Myron S Czuczman, Ann S LaCasce, John F Gerecitano, John P Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi-Lin Chiu,[...]. Lancet Oncol 2010
522
9

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.
Julia Richter, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen Leich, Birgit Burkhardt, Maciej Rosolowski, Ole Ammerpohl, Rabea Wagener, Stephan H Bernhart,[...]. Nat Genet 2012
277
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.